Determination of two-photon exchange amplitudes from elastic electron-proton scattering data

Using the available cross section and polarization data for elastic electron-proton scattering, we provide an extraction of the two-photon exchange amplitudes at a common value of four-momentum transfer, around Q^2 = 2.5 GeV^2. This analysis also predicts the e^+ p / e^- p elastic scattering cross section ratio, which will be measured by forthcoming experiments.Comment: 4 pages, 5 figures, updated error analysi

SOSIALISASI KOMISI YUDISIAL MALUKU UNTUK MEMBANGUN PERADILAN BERSIH DI NEGERI LATUHALAT

Sosialisasi peradilan bersih dilaksanakan di desa Latuhalat guna untuk meningkatkan pemahaman dan peran masyarakat Negeri Latuhalat dengan tujuan untuk menciptakan peran masyarakat dalam mewujudkan peradilan yang bersih yang bebas dari praktek kolusi, korupsi,dan nepotisme agar terwujudnya keadilan dalam masyarakat, pemahaman masarakat terkait peradilan bersih dan lembaga terkait yang berperan penting dalam menciptakan peradilan bersih seperti Komisi Yudisial sangatlah penting. Komisi yudisial merupakan lembaga tinggi negara yang independen yang bergerak di bidang pengawasan hakim, kegiatan ini dilaksanakan pada tangal 3 november sampai 4 november 2021 kantor desa Latuahalat. Sasaran yang ditujukan adalah masyarakat Negeri Latuhalat metode yang digunakan adalah memberikan edukasi langsung dengan cara membagai brosur berisikan alur alur pelaporan hakim yang melanggar kode etik. Dalam kegiatan ini ada dua tahapan yang dilalui yang pertama komisi yudisial mensosialisasikan kepada mahasiswa KKN Negeri Latuhalat, yang kedua mahasiswa membagikan brosur dan buku mini ke masyarakat sekaligus menerangkan terkait isi dari brosur dan buku tersebut. Dengan adanya sosialisasi peradilan bersih ini maka masyarakat akan lebih memahami peran - perannya dalam mewujudkan peradilan yang bersih. Peradilan bersih merupakan hal yang sangat penting dalam mewujudkan keadilan dalam masyarakat, salah satu peran masyarakat dalam mewujudkan peradilan bersih adalah memahami alur - alur pelaporan hakim yang melanggar kode etik dan pedoman perilaku hakim sesuai peraturan perundang undangan yang berlaku

Neutrino Quasielastic Scattering on Nuclear Targets: Parametrizing Transverse Enhancement (Meson Exchange Currents)

We present a parametrization of the observed enhancement in the transverse electron quasielastic (QE) response function for nucleons bound in carbon as a function of the square of the four momentum transfer ($Q^2$) in terms of a correction to the magnetic form factors of bound nucleons. The parametrization should also be applicable to the transverse cross section in neutrino scattering. If the transverse enhancement originates from meson exchange currents (MEC), then it is theoretically expected that any enhancement in the longitudinal or axial contributions is small. We present the predictions of the "Transverse Enhancement" model (which is based on electron scattering data only) for the $\nu_\mu, \bar{\nu}_\mu$ differential and total QE cross sections for nucleons bound in carbon. The $Q^2$ dependence of the transverse enhancement is observed to resolve much of the long standing discrepancy in the QE total cross sections and differential distributions between low energy and high energy neutrino experiments on nuclear targets.Comment: Revised Version- July 21, 2011: 17 pages, 20 Figures. To be published in Eur. Phys. J.

Light-cone QCD Sum Rules for the Λ\Lambda Baryon Electromagnetic Form Factors and its magnetic moment

We present the light-cone QCD sum rules up to twist 6 for the electromagnetic form factors of the $\Lambda$ baryon. To estimate the magnetic moment of the baryon, the magnetic form factor is fitted by the dipole formula. The numerical value of our estimation is $\mu_\Lambda=-(0.64\pm0.04)\mu_N$, which is in accordance with the experimental data and the existing theoretical results. We find that it is twist 4 but not the leading twist distribution amplitudes that dominate the results.Comment: 13 page, 7 figures, accepted for publication in Euro. Phys. J.

Charged pion form factor between Q^2=0.60 and 2.45 GeV^2. II. Determination of, and results for, the pion form factor

The charged pion form factor, Fpi(Q^2), is an important quantity which can be used to advance our knowledge of hadronic structure. However, the extraction of Fpi from data requires a model of the 1H(e,e'pi+)n reaction, and thus is inherently model dependent. Therefore, a detailed description of the extraction of the charged pion form factor from electroproduction data obtained recently at Jefferson Lab is presented, with particular focus given to the dominant uncertainties in this procedure. Results for Fpi are presented for Q^2=0.60-2.45 GeV^2. Above Q^2=1.5 GeV^2, the Fpi values are systematically below the monopole parameterization that describes the low Q^2 data used to determine the pion charge radius. The pion form factor can be calculated in a wide variety of theoretical approaches, and the experimental results are compared to a number of calculations. This comparison is helpful in understanding the role of soft versus hard contributions to hadronic structure in the intermediate Q^2 regime.Comment: 18 pages, 11 figure

The lead-glass electromagnetic calorimeters for the magnetic spectrometers in Hall C at Jefferson Lab

The electromagnetic calorimeters of the various magnetic spectrometers in Hall C at Jefferson Lab are presented. For the existing HMS and SOS spectrometers design considerations, relevant construction information, and comparisons of simulated and experimental results are included. The energy resolution of the HMS and SOS calorimeters is better than $\sigma/E \sim 6$, and pion/electron ($\pi/e$) separation of about 100:1 has been achieved in energy range 1 -- 5 GeV. Good agreement has been observed between the experimental and simulated energy resolutions, but simulations systematically exceed experimentally determined $\pi^-$ suppression factors by close to a factor of two. For the SHMS spectrometer presently under construction details on the design and accompanying GEANT4 simulation efforts are given. The anticipated performance of the new calorimeter is predicted over the full momentum range of the SHMS. Good electron/hadron separation is anticipated by combining the energy deposited in an initial (preshower) calorimeter layer with the total energy deposited in the calorimeter.Comment: 22 pages, 33 figure

Measurement of the Nucleon Structure Function F2 in the Nuclear Medium and Evaluation of its Moments

We report on the measurement of inclusive electron scattering off a carbon target performed with CLAS at Jefferson Laboratory. A combination of three different beam energies 1.161, 2.261 and 4.461 GeV allowed us to reach an invariant mass of the final-state hadronic system W~2.4 GeV with four-momentum transfers Q2 ranging from 0.2 to 5 GeV2. These data, together with previous measurements of the inclusive electron scattering off proton and deuteron, which cover a similar continuous two-dimensional region of Q2 and Bjorken variable x, permit the study of nuclear modifications of the nucleon structure. By using these, as well as other world data, we evaluated the F2 structure function and its moments. Using an OPE-based twist expansion, we studied the Q2-evolution of the moments, obtaining a separation of the leading-twist and the total higher-twist terms. The carbon-to-deuteron ratio of the leading-twist contributions to the F2 moments exhibits the well known EMC effect, compatible with that discovered previously in x-space. The total higher-twist term in the carbon nucleus appears, although with large systematic uncertainites, to be smaller with respect to the deuteron case for n<7, suggesting partial parton deconfinement in nuclear matter. We speculate that the spatial extension of the nucleon is changed when it is immersed in the nuclear medium.Comment: 37 pages, 15 figure

The International Pulsar Timing Array: First data release

International audienceThe highly stable spin of neutron stars can be exploited for a variety of (astro)physical investigations. In particular, arrays of pulsars with rotational periods of the order of milliseconds can be used to detect correlated signals such as those caused by gravitational waves. Three such 'pulsar timing arrays' (PTAs) have been set up around the world over the past decades and collectively form the 'International' PTA (IPTA). In this paper, we describe the first joint analysis of the data from the three regional PTAs, i.e. of the first IPTA data set. We describe the available PTA data, the approach presently followed for its combination and suggest improvements for future PTA research. Particular attention is paid to subtle details (such as underestimation of measurement uncertainty and long-period noise) that have often been ignored but which become important in this unprecedentedly large and inhomogeneous data set. We identify and describe in detail several factors that complicate IPTA research and provide recommendations for future pulsar timing efforts. The first IPTA data release presented here (and available on-line) is used to demonstrate the IPTA's potential of improving upon gravitational-wave limit

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation &lt;92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p&lt;0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p&lt;0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research